Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 6c. Side effects causing cessation of therapy – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 1a.'Clinical apnea' after initiation of treatment – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 1b. 'Clinical apnea' after initiation of treatment – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 2a. Failed apnea reduction after 2–7 days – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3a. Chronic lung disease at 36 weeks' postmenstrual age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3b. Chronic lung disease at 36 weeks' postmenstrual age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3c. Chronic lung disease at 36 weeks' postmenstrual age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 4a. Death (at any time during initial hospitalization) – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 4b. Death (at any time during initial hospitalization) – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 5a.Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 6a. Side effects causing cessation of therapy – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 6b. Side effects causing cessation of therapy – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 2c. Need for positive pressure ventilation after initiation of treatment – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3a. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram compared to no treatment for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3b. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or 3c. Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation) – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea Doxapram for the prevention and treatment of apnea in preterm infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment (8 doses, 1000 IU/m2, IM) vs continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV) Thromboembolism ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs no treatment or placebo Subjective improvement or cure of POP symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs pelvic floor muscle training Objective improvement or cure of POP symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs pelvic floor muscle training Generic quality of life measures · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs pelvic floor muscle training Participant adherence to intervention · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs pelvic floor muscle training Minor adverse effects: vaginal events · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs pelvic floor muscle training Major adverse events · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs devices such Subjective improvement or cure of POP symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs devices such Improvement or cure of associated sexual symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs devices such Objective improvement or cure of POP symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs devices such Generic quality of life measures · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs devices such Participant adherence to intervention · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs no treatment or placebo Improvement or cure of associated sexual symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs devices such Minor adverse effects: vaginal events · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs devices such Major adverse events · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs surgery Subjective improvement or cure of POP symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs surgery Improvement or cure of associated sexual symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs surgery Objective improvement or cure of POP symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs surgery Generic quality of life measures · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs surgery Participant adherence to intervention · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs surgery Minor adverse effects: vaginal events · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs surgery Major adverse events · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs no treatment or placebo Objective improvement or cure of POP symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs no treatment or placebo Generic quality of life measures · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs no treatment or placebo Participant adherence to intervention · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs no treatment or placebo Minor adverse effects: vaginal events · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs no treatment or placebo Major adverse events · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs pelvic floor muscle training Subjective improvement or cure of POP symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |
Oestrogen therapy alone vs pelvic floor muscle training Improvement or cure of associated sexual symptoms · women with POP Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women (2023) · Cochrane | no estimate extracted | NR | No studies |